{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-097036","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.529579+00:00","generated_at":"2026-05-31T09:23:33.722895+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts","bullets":["Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.","Net loss Q2 2024 $1.3M vs $2.1M; H1 net loss $2.7M, $1.5M improvement from H1 2023.","Gross margin improved to 42% in H1 2024 from 32% in H1 2023 due to cost reductions.","Cash and equivalents $3.7M as of June 30, 2024; raised $3.3M net from May 2024 offering.","Phase 1 VNS trial results with Feinstein Institutes; ClearUP 2.0 launched; lease and logistics savings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-097036","json":"https://secwatch.observer/filing/0000950170-24-097036.json","markdown":"https://secwatch.observer/filing/0000950170-24-097036.md","text":"https://secwatch.observer/filing/0000950170-24-097036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/0000950170-24-097036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/tivc-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:33.722895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}